Stocksigma LogoStocksigma Logo

Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds

Astec LifeSciences reported a 3% YoY decline in Q2FY27 consolidated total income to ₹72.6 crore, alongside a widened EBITDA loss of ₹19.2 crore versus a

Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds

Astec Lifesciences Ltd · Press Release · 27 Oct 2026, 12:37 am

Astec LifeSciences Reports Widened Losses in Q2FY27 Amid Agrochemical Headwinds Astec LifeSciences reported a 3% YoY decline in Q2FY27 consolidated total income to ₹72.6 crore, alongside a widened EBITDA loss of ₹19.2 crore versus a loss of ₹5.6 crore in Q2FY26. Net loss expanded to ₹37.4 crore from ₹24.4 crore YoY, impacted by subdued demand, lower realizations, elevated input costs, and an inventory write-down of ₹3 crore. Segmentally, enterprise revenue dropped 6% YoY to ₹57.0 crore, while CDMO grew 15% YoY to ₹15.0 crore. Geographically, domestic revenue rose 32% YoY to ₹43.1 crore, offset by a 30% export decline to ₹28.9 crore.

Original exchange filing (PDF)

More announcements from Astec Lifesciences Ltd

All Astec Lifesciences Ltd announcements